FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3111716646> ?p ?o ?g. }

• W3111716646 endingPage "1383" @default.
• W3111716646 startingPage "1373" @default.
• W3111716646 abstract "Purpose This study aims to explore the radioprotective effects of recombinant human erythropoietin (rhEPO) on rats' submandibular gland hypofunction induced by irradiation (IR). Materials and Methods Thirty rats were divided into 3 groups: 1) control group, 2) IR group, and 3) IR + rhEPO group. The IR group and IR + rhEPO group received a single dose of 15 Grays (Gy) (0.98 Gy/min), plus, the IR + rhEPO group also received subcutaneous administration of rhEPO at a dose of 3,000 IU/kg body weight 3 days before irradiation and then repeated every 24 hours for the first 2 weeks after irradiation. Immunohistochemistry analysis to erythropoietin receptor was performed to detect the levels of erythropoietin receptor in submandibular glands with or without radiation. Ninety days after irradiation, the salivary flow rates were assessed, and the submandibular gland of every rat was subjected to hematoxylin and eosin staining and immunohistochemical staining with antiaquaporin 5 and anti–proliferating cell nuclear antigen antibodies. Apoptosis was examined by the terminal deoxynucleotidyl transferase biotin-dUDP nick end-labeling assay. In addition, to examine the protective role of rhEPO on human submandibular gland cells, the apoptotic and proliferation rate of cells under a radiation dose of 8 Gy was detected. One-way analysis of variance was carried out to analyze the results of each group, and the P value was set at 0.05. Results Erythropoietin receptor was expressed in the submandibular glands at a low level under normal conditions but upregulated after irradiation. rhEPO administration remarkably alleviated gland atrophy, increased salivary flow rates with upregulation of aquaporin-5 compared with the IR group. In addition, fewer apoptotic cells and more proliferative cells were observed in the IR + rhEPO group compared with the IR group, both in vivo and in vitro. Conclusions rhEPO administration may be a useful countermeasure to mitigate submandibular gland hypofunction after therapeutic radiation exposure. This study aims to explore the radioprotective effects of recombinant human erythropoietin (rhEPO) on rats' submandibular gland hypofunction induced by irradiation (IR). Thirty rats were divided into 3 groups: 1) control group, 2) IR group, and 3) IR + rhEPO group. The IR group and IR + rhEPO group received a single dose of 15 Grays (Gy) (0.98 Gy/min), plus, the IR + rhEPO group also received subcutaneous administration of rhEPO at a dose of 3,000 IU/kg body weight 3 days before irradiation and then repeated every 24 hours for the first 2 weeks after irradiation. Immunohistochemistry analysis to erythropoietin receptor was performed to detect the levels of erythropoietin receptor in submandibular glands with or without radiation. Ninety days after irradiation, the salivary flow rates were assessed, and the submandibular gland of every rat was subjected to hematoxylin and eosin staining and immunohistochemical staining with antiaquaporin 5 and anti–proliferating cell nuclear antigen antibodies. Apoptosis was examined by the terminal deoxynucleotidyl transferase biotin-dUDP nick end-labeling assay. In addition, to examine the protective role of rhEPO on human submandibular gland cells, the apoptotic and proliferation rate of cells under a radiation dose of 8 Gy was detected. One-way analysis of variance was carried out to analyze the results of each group, and the P value was set at 0.05. Erythropoietin receptor was expressed in the submandibular glands at a low level under normal conditions but upregulated after irradiation. rhEPO administration remarkably alleviated gland atrophy, increased salivary flow rates with upregulation of aquaporin-5 compared with the IR group. In addition, fewer apoptotic cells and more proliferative cells were observed in the IR + rhEPO group compared with the IR group, both in vivo and in vitro. rhEPO administration may be a useful countermeasure to mitigate submandibular gland hypofunction after therapeutic radiation exposure." @default.
• W3111716646 created "2020-12-21" @default.
• W3111716646 creator A5033505377 @default.
• W3111716646 creator A5033632697 @default.
• W3111716646 creator A5034490367 @default.
• W3111716646 creator A5039541195 @default.
• W3111716646 creator A5045858425 @default.
• W3111716646 creator A5083658918 @default.
• W3111716646 date "2021-06-01" @default.
• W3111716646 modified "2023-09-26" @default.
• W3111716646 title "Erythropoietin Plays a Protective Role in Submandibular Gland Hypofunction Induced by Irradiation" @default.
• W3111716646 cites W1556016315 @default.
• W3111716646 cites W1757407923 @default.
• W3111716646 cites W1969719900 @default.
• W3111716646 cites W1988795010 @default.
• W3111716646 cites W1998651106 @default.
• W3111716646 cites W2039070114 @default.
• W3111716646 cites W2046040069 @default.
• W3111716646 cites W2052574732 @default.
• W3111716646 cites W2062035796 @default.
• W3111716646 cites W2067170629 @default.
• W3111716646 cites W2071328905 @default.
• W3111716646 cites W2085874330 @default.
• W3111716646 cites W2103177079 @default.
• W3111716646 cites W2113534144 @default.
• W3111716646 cites W2154612768 @default.
• W3111716646 cites W2162264368 @default.
• W3111716646 cites W2165277307 @default.
• W3111716646 cites W2175224397 @default.
• W3111716646 cites W2294279660 @default.
• W3111716646 cites W2365000872 @default.
• W3111716646 cites W2541991908 @default.
• W3111716646 cites W2550064952 @default.
• W3111716646 cites W2640661976 @default.
• W3111716646 cites W2767046715 @default.
• W3111716646 cites W2794852855 @default.
• W3111716646 cites W2904206173 @default.
• W3111716646 cites W2969681245 @default.
• W3111716646 cites W2990409567 @default.
• W3111716646 cites W3008298474 @default.
• W3111716646 cites W3012736582 @default.
• W3111716646 cites W3033264701 @default.
• W3111716646 doi "https://doi.org/10.1016/j.joms.2020.12.001" @default.
• W3111716646 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33412114" @default.
• W3111716646 hasPublicationYear "2021" @default.
• W3111716646 type Work @default.
• W3111716646 sameAs 3111716646 @default.
• W3111716646 citedByCount "2" @default.
• W3111716646 countsByYear W31117166462022 @default.
• W3111716646 crossrefType "journal-article" @default.
• W3111716646 hasAuthorship W3111716646A5033505377 @default.
• W3111716646 hasAuthorship W3111716646A5033632697 @default.
• W3111716646 hasAuthorship W3111716646A5034490367 @default.
• W3111716646 hasAuthorship W3111716646A5039541195 @default.
• W3111716646 hasAuthorship W3111716646A5045858425 @default.
• W3111716646 hasAuthorship W3111716646A5083658918 @default.
• W3111716646 hasConcept C125473707 @default.
• W3111716646 hasConcept C126322002 @default.
• W3111716646 hasConcept C134018914 @default.
• W3111716646 hasConcept C142724271 @default.
• W3111716646 hasConcept C154113507 @default.
• W3111716646 hasConcept C190283241 @default.
• W3111716646 hasConcept C196795494 @default.
• W3111716646 hasConcept C204232928 @default.
• W3111716646 hasConcept C2778534260 @default.
• W3111716646 hasConcept C2778937882 @default.
• W3111716646 hasConcept C2780266248 @default.
• W3111716646 hasConcept C2781172350 @default.
• W3111716646 hasConcept C31102739 @default.
• W3111716646 hasConcept C55493867 @default.
• W3111716646 hasConcept C71924100 @default.
• W3111716646 hasConcept C86803240 @default.
• W3111716646 hasConceptScore W3111716646C125473707 @default.
• W3111716646 hasConceptScore W3111716646C126322002 @default.
• W3111716646 hasConceptScore W3111716646C134018914 @default.
• W3111716646 hasConceptScore W3111716646C142724271 @default.
• W3111716646 hasConceptScore W3111716646C154113507 @default.
• W3111716646 hasConceptScore W3111716646C190283241 @default.
• W3111716646 hasConceptScore W3111716646C196795494 @default.
• W3111716646 hasConceptScore W3111716646C204232928 @default.
• W3111716646 hasConceptScore W3111716646C2778534260 @default.
• W3111716646 hasConceptScore W3111716646C2778937882 @default.
• W3111716646 hasConceptScore W3111716646C2780266248 @default.
• W3111716646 hasConceptScore W3111716646C2781172350 @default.
• W3111716646 hasConceptScore W3111716646C31102739 @default.
• W3111716646 hasConceptScore W3111716646C55493867 @default.
• W3111716646 hasConceptScore W3111716646C71924100 @default.
• W3111716646 hasConceptScore W3111716646C86803240 @default.
• W3111716646 hasFunder F4320321001 @default.
• W3111716646 hasFunder F4320322300 @default.
• W3111716646 hasFunder F4320326171 @default.
• W3111716646 hasFunder F4320326270 @default.
• W3111716646 hasFunder F4320335777 @default.
• W3111716646 hasIssue "6" @default.
• W3111716646 hasLocation W31117166461 @default.
• W3111716646 hasOpenAccess W3111716646 @default.
• W3111716646 hasPrimaryLocation W31117166461 @default.
• W3111716646 hasRelatedWork W1982845946 @default.

• next